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Uncoupling protein 2 (UCP2) is an inner mitochondrial membrane protein that belongs to the uncoupling protein family and plays
an important role in lowering mitochondrial membrane potential and dissipating metabolic energy with prevention of oxidative
stress accumulation. In the present article, we will review the evidence that UCP2, as a consequence of its roles within the
mitochondria, represents a critical player in the predisposition to vascular disease development in both animal models and in
humans, particularly in relation to obesity, diabetes, and hypertension. The deletion of the UCP2 gene contributes to
atherosclerosis lesion development in the knockout mice, also showing significantly shorter lifespan. The UCP2 gene
downregulation is a key determinant of higher predisposition to renal and cerebrovascular damage in an animal model of
spontaneous hypertension and stroke. In contrast, UCP2 overexpression improves both hyperglycemia- and high-salt
diet-induced endothelial dysfunction and ameliorates hypertensive target organ damage in SHRSP. Moreover, drugs (fenofibrate
and sitagliptin) and several vegetable compounds (extracts from Brassicaceae, berberine, curcumin, and capsaicin) are able to
induce UCP2 expression level and to exert beneficial effects on the occurrence of vascular damage. As a consequence, UCP2
becomes an interesting therapeutic target for the treatment of common human vascular diseases.
1. Introduction
Uncoupling proteins (UCPs) belong to the family of
mitochondrial transporter proteins and are important for
lowering mitochondrial membrane potential and dissipating
metabolic energy as heat, maintenance of respiration, glucose
disposal rate, insulin secretion, and prevention of reactive
oxygen species (ROS) accumulation [1, 2].
Five UCPs have been characterized in mammals: UCP1–
UCP3 that are evolutionary related and UCP4 and UCP5
(also known as BMCP1) that are more divergent [3]. UCP2
is a member of the mitochondrial anion carrier family and
displays 60% sequence identity with the well-known thermo-
genic UCP1 present in the brown adipose tissue [2]. The
genes encoding UCP2 and UCP3 are adjacent in all species,
and they map on mouse chromosome 7, rat chromosome 1,
and human chromosome 11 [3]. UCP1–UCP3 genes share
six coding exons and have two additional nontranslated
exons [4]. UCP2 is highly conserved across species with
a 95% homology in the amino acid sequence between rat
and human [4]. The UCP2 promoter contains putative
response elements for peroxisome proliferator-activated
receptor (PPARγ, PPARα, and PPARδ), sterol-responsive
element-binding protein (SREBP), and cyclic AMP response
element-binding protein (CREB) [5–7].
Several regulatory factors of UCP2 act at both transcrip-
tional and posttranscriptional levels. Purine nucleotides have
been recognized to negatively regulate UCP2, whereas
unsaturated free fatty acids (FFA), glucose, retinoic acid,
lipopolysaccharides, and ROS have been reported to activate
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UCP2 [8, 9]. In particular, FFA have been demonstrated to
strongly enhance UCP2 mRNA expression acting on either
PPAR or SREBP element [10].
UCP2 is highly expressed in human white adipose tissue.
Considerable amounts are also expressed in the skeletal mus-
cle, heart, lung, spleen, thymus, cells of the immune system,
and vascular cells, whereas lower amounts are expressed in
the brain, liver, and kidney [11]. All members of the UCP
family are integral transmembrane proteins, located within
the inner mitochondrial membrane. They are characterized
by three repeat domains each formed by two α-helix regions
in the lipid bilayer. The carbossi and aminoterminal regions
reside into the mitochondrial intermembrane space whereas
the α-helix regions are connected by long hydrophilic loops
in the matrix side (Figure 1) [12, 13].
UCP2 is involved in the control of uncoupling of proton
flux within the mitochondria. In particular, protons gener-
ated across the inner mitochondrial membrane during oxida-
tion of substrates reenter in the matrix through UCPs instead
of the ATP synthase [14]. Therefore, the proton gradient is
converted into heat energy and not in ATP (Figure 1). The
involvement of UCP2 in ATP production was demonstrated
for the first time in pancreatic β-cells [15]. UCP2, unlike
UCP1, appears to contribute mainly to the regulation of
ATP [16], mitochondrial membrane potential (Δψ) [17], cel-
lular calcium homeostasis [17], cell survival [18], lipid
metabolism [19], and the generation of ROS [19, 20]. UCP2
belongs to the mitochondrial antioxidant mechanisms [21],
and as such, it contributes to maintaining the balance
between production and clearance of ROS.
Due to the roles that UCP2 plays within the mito-
chondria, it is clear that a decrease in UCP2 expression
may be strongly implicated in the genesis of mitochondrial
dysfunction, ROS accumulation, and cell death and, there-
fore, in the pathogenesis of several diseases.
Whereas controversial evidence exists, within the cardio-
vascular system, in regard to the role that UCP2 plays in the
pathogenesis of left ventricular hypertrophy [22, 23], more
robust and convincing findings were reported in relation to
UCP2 and its contribution to vascular damage.
The present article will review the available evidence
demonstrating the direct contributory role of UCP2, through
an increased rate of ROS generation, in the pathogenesis of
vascular diseases, particularly within the context of diabetes
and hypertension, therefore supporting it as an attractive
therapeutic tool for the treatment of the vascular complica-
tions associated with these common pathological conditions.
2. UCP2 and the Pathogenesis of
Vascular Diseases
An increased ROS accumulation is an important mecha-
nism involved in the development of vascular diseases.
At physiological concentrations, ROS, produced from both
cytoplasmic and mitochondrial sources, represent an intra-
cellular and intercellular second messenger that modulates
several downstream signaling molecules leading to vascular
reactivity [24], vascular smooth muscle cell growth and
migration, expression of proinflammatory mediators, and
remodeling of the extracellular matrix [25]. On the other
hand, an accumulation of ROS is dangerous. At the level
of mitochondria, it leads to damage of mitochondrial pro-
teins, lipids, and DNA with consequent alteration of the
mitochondrial function, a further increase in ROS, and, at
the vascular level, development of endothelial oxidative stress
[26]. In fact, mitochondrial dysfunction causing excessive
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Figure 1: Overview of UCP2 localization and function. UCP2 is located within the inner mitochondrial membrane where it uncouples proton
flux with the consequent regulation of ATP synthesis. ROS activates UCP2. The latter, through a negative feedback mechanism, decreases
ROS and protects vascular cells from the oxidative stress-dependent damage. See text for details. OMM: outer mitochondrial membrane;
IMS: intermembrane space; IMM: inner mitochondrial membrane.
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ROS production contributes to the pathogenesis of several
diseases including cardiovascular diseases [27]. It has been
demonstrated that UCP2 proton leak is activated directly
by superoxide and ROS by-products [9], thus creating a local
feedback circuit. Although the mechanism by which UCP2 is
activated by ROS is not completely understood, reactive alde-
hydes derived from lipid peroxidation have been suggested to
be the ROS able to induce UCP2 activation [28]. The known
intracellular signaling pathways mediating UCP2 gene acti-
vation are the AMPK/SIRT1/PPARα axis [29] and the
cAMP-dependent protein kinase [30, 31].
Once activated, UCP2 modulates several proinflamma-
tory and proatherogenic signals working in the vasculature
and involved in the pathogenesis of diseases. Among them,
tumor necrosis factor α (TNFα) is the most relevant. Thus,
the relationship between TNFα and UCP2 expression levels
appears to be of importance in assessing the risk of vascular
damage. It has been reported that TNFα directly downregu-
lates adiponectin [32] thus contributing to the development
of vascular insulin resistance and to decreased UCP2 levels
in the aorta. On the other hand, higher levels of adiponectin
might induce UCP2 overexpression in the aorta attenuating
the vascular damage [33]. Another mechanism involved in
the inhibitory effect of TNFα on UCP2 expression is the
nitric oxide- (NO-) dependent pathway that involves the
inducible nitric oxide synthase (iNOS) expression in both
endothelial and vascular smooth muscle cells [34]. Thus,
based on the evidence that TNFα downregulates UCP2
expression level, a pretreatment with an anti-TNFα antibody
has been attempted in vivo [33]. TNFα and insulin share an
antagonistic effect on UCP2 expression level in vascular cells
and also in the aorta in vivo. Moderate hyperinsulinemia in
response to insulin resistance or lowering of TNFα levels
within the aorta attenuated vascular damage [33]. This pro-
tective effect was mediated by increased UCP2 expression
level through a decrease in iNOS expression. Insulin might
also reduce NF-κB activation in the aorta, and as a conse-
quence, it may favor UCP2 overexpression and may protect
against the vascular damage.
A part from TNFα, UCP2 modulates the expression of
other inflammatory cytokines within the vascular tissue. In
fact, a significant increase in the protein levels of cutaneous
T-cell-attracting chemokine (CTACK), chemokine (C-X-C
motif) ligand-16 (CXCL16), eotaxin-2, fractalkine, and B-
lymphocyte chemoattractant (BLC) was reported in the
UCP2 gene-knockout mice [35]. The upregulation of these
inflammatory mediators contributed to the ischemic brain
damage and to the neuronal death after transient focal ische-
mia in the UCP2-knockout model. On the other hand, UCP2
overexpression in monocytes led to a significant reduction of
β2 integrin level with a consequent decrease in monocyte
adhesion and transendothelial migration [36]. The latter
phenomena can contribute to the reduction in atheroscle-
rotic plaque formation in the presence of higher UCP2 level.
UCP2 has also been reported to prevent mitochondrial-
induced cell death [18]. Although the precise mechanism is
not completely understood, several authors suggested that
UCP2, acting on multiple aspects of mitochondrial functions
(Δψ, ATP/ADP ratio, calcium transport, and levels of ROS),
may reduce the activation of the mitochondrial permeability
transition pore (mPTP), the main activator of mitochondrial
death cascade [17].
2.1. Atherosclerosis. Atherosclerosis is a disease of the large
vessels where it leads to plaque deposition and narrowing
of the lumen with distal ischemia. Microvascular disease
affects the small blood vessels of highly perfused organs with
low vascular resistance such as the retina, kidney, heart, and
brain [37]. The pathogenesis of both macro- and microvas-
cular diseases is associated with several risk factors and
common pathological conditions such as hypertension,
diabetes, obesity, and dyslipidemia [38, 39]. This process
involves multiple molecular mechanisms, primarily oxidative
stress and inflammation.
Evidence of a direct role of UCP2 in the promotion of
atherosclerosis in vivo was first obtained in the UCP2 gene-
knockout mice that developed multiple atherosclerotic
lesions in several districts, with a significantly shorter lifespan
[40, 41]. Moreover, the bone marrow transplantation from
UCP2-deficient mice to low-density lipoprotein receptor
(LDLR−/−) mice markedly increased atherosclerotic lesion
size [42]. An indirect evidence of the pathogenic link between
UCP2 and vascular damage was provided by the high-fat
diet-fed BATIRKO mice that manifested higher oxidative
stress in the aorta in association with lower UCP2 expression
level [33]. The decrease in UCP2 level in the aorta was
strongly inversely correlated with lipid accumulation and
lesion area in the normoinsulinemic BATIRKO mice [33].
On the other hand, UCP2 overexpression has been
shown to ameliorate both hyperglycemia and obesity-
induced endothelial dysfunction [43, 44], and it may help
to prevent the development of atherosclerosis in patients
with increased ROS, such as those with diabetes, obesity, or
hypertension [45].
2.2. Diabetes. The pathogenetic link between UCP2 and
metabolic diseases, involving the associated vascular damage,
is complex. First of all, UCP2 might play an important role in
the regulation of energy expenditure and it is likely to con-
tribute itself to obesity and type 2 diabetes mellitus
(T2DM). In fact, reduced UCP gene expression was found
in tissues of obese subjects and in the kidneys of T2DM
patients [46, 47]. Furthermore, few case-control genetic asso-
ciation studies reported significant associations between
UCP2 gene polymorphisms and obesity and diabetes in
humans [47–52]. On the other hand, both obese and diabetic
patients have associated vascular complications such as
atherosclerosis [53] and retinopathy [54] where UCP2 may
play a direct contributory pathogenetic role. In this regard,
the early stages of diabetic retinopathy, the most common
complication of diabetes, are characterized by microvascular
cell damage [54] associated with the thickening of the capil-
lary endothelial basement membrane and pericyte apoptosis
induced by hyperglycemia [55]. Previous investigations into
the molecular mechanisms that cause this common vascular
complication of diabetes focused on the vascular endothelial
growth factor (VEGF) [56, 57]. Recently, the important role
played by increased mitochondrial ROS production in the
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complications of diabetes, including retinopathy, has been
emphasized [58]. Of note, UCP2, as a mediator of the mito-
chondrial ROS pathway, appears to be involved [59].
Recent studies investigated the possible inhibition of high
glucose-induced apoptosis by UCP2 in human umbilical vein
endothelial cells (HUVEC) [60] and demonstrated that
UCP2 plays an antiapoptotic role in this experimental
setting. The beneficial effects of UCP2 on the vascular conse-
quences of hyperglycemia are interesting based on the known
observation that glucose itself is responsible for the vascular
complications and that, as a downstream effector of hyper-
glycemia, oxidative stress is involved in the development of
vascular dysfunction. Glucose can induce ROS generation
by multiple mechanisms including the mitochondrial respi-
ratory chain [61]. The endogenous antioxidant system
should counterbalance the ROS production in the vascula-
ture, but it fails to do so in diabetes, leading to oxidative
stress accumulation and damage [62]. Consequently, the
restoration of the mitochondrial antioxidant mechanisms
can represent a useful approach for the prevention and
treatment of diabetic vascular complications and of the
consequent clinical events. The potential beneficial effect
of this strategy is supported by evidence that a common
−866G>A variant in the promoter of the UCP2 gene,
where the A allele associates with increased gene expres-
sion [49], decreased the risk of myocardial infarction,
angina pectoris, coronary artery bypass grafting (CABG),
and sudden death in TDM2 patients [52, 63].
2.3. Hypertension. A tight link exists also between UCP2 and
vascular damage in hypertensive disease, particularly in the
presence of excess salt intake. Abundant evidence in the liter-
ature demonstrates that high salt (HS) intake is a major
factor increasing systemic blood pressure (BP) levels and
thereby vascular damage [64, 65]. HS diet plays also direct
harmful effects independent of its impact on BP levels [66].
The mechanisms underlying the direct deleterious effect
of HS intake on the vascular bed have not been fully
understood. Recent studies demonstrated an important
role of UCP2 in the salt sensitivity and its vascular conse-
quences. In this regard, it has been shown that HS diet
caused enhanced BP levels and an impairment of vascular
function (reduction in endothelium-dependent relaxation)
in UCP2−/−mice [67, 68]. On the other hand, overexpression
of UCP2 was able to ameliorate the salt-induced vascular
dysfunction [69]. The beneficial effect of UCP2 was mediated
by decreased superoxide production and increased NO
bioavailability. In fact, UCP2 deficiency exacerbated the
HS-induced reduction of NO bioavailability and increased
superoxide production.
Consistent with the above-mentioned evidence, the gene
encoding UCP2 has been underscored as a contributory fac-
tor to the HS diet-dependent vascular disease in an animal
model of spontaneous hypertension, renal damage, and
stroke. In fact, it was found that UCP2 maps nearby the lod
score peak of a quantitative trait locus for stroke (STR1) in
the HS-fed stroke-prone spontaneously hypertensive rat
(SHRSP), a strain with increased susceptibility to vascular
damage [70]. Recent studies performed in this animal model,
aimed at the further dissection of the pathogenetic contribu-
tory role of UCP2 in the vascular disease of the strain,
showed that a differential regulation of UCP2 expression,
and of all proteins that lie upstream in the UCP2 regulatory
pathway, was present in the kidneys of SHRSP, but not in
those of the stroke-resistant SHR (SHRSR) upon the stroke-
permissive HS dietary regimen. In particular, we obtained
evidence of reduced UCP2 gene and protein expression in
the kidneys of stroke-prone rats and of increased expression
in the kidneys of stroke-resistant rats. Moreover, knocking
out the UCP2 gene in mesangial renal cells led to increased
oxidative stress, reduced ATP synthesis, and increased cell
necrosis [71, 72]. Furthermore, a recent study demonstrated
that proximal tubular epithelial cells from the SHRSP strain,
once exposed to the high-NaCl medium, showed a significant
UCP2 downregulation with an increased rate of cell inflam-
mation and necrosis. Notably, the renal tubular epithelial
cells recovered their healthy status after exposure to exoge-
nous recombinant UCP2 despite the presence of high-NaCl
medium [73]. These results strongly suggest that changes in
UCP2 expression contribute to the higher predisposition of
HS-fed SHRSP to renal damage development.
Similar findings were more recently obtained in the brain
of the SHRSP, compared to the SHRSR, with evidence of a
significant contributory role of reduced UCP2 gene and
protein expression in the higher stroke predisposition of
the strain [74].
Moreover, a striking downregulation of UCP2 gene
and protein expression was found in relation to both
hypertension and ageing in the brain, heart, and kidneys
of the SHRSP, but not of the SHRSR [74]. In fact, the
age- and hypertension-related UCP2 suppression in SHRSP
associated with a higher oxidative stress accumulation and
inflammation in all tissues examined, along with an increased
rate of interstitial, perivascular, peritubular, and glomerular
fibrosis in the kidneys; with increased percentage of perivas-
cular and myocardial interstitial collagen accumulation in
the heart; and with higher occurrence of ischemic and
hemorrhagic lesions in the brain [75]. The latter study
supported the concept that, through greater oxygen con-
sumption, reduced mitochondrial membrane potential,
and reduced ROS generation, all underlying positive influ-
ences on biological ageing, UCP2 may also contribute to
expand lifespan, as stated in the “uncoupling-to-survive”
hypothesis [76].
Thus, HS diet, high BP levels, and ageing are able to
turn off tissue UCP2 gene expression only in the SHRSP
animal model through still unexplained mechanisms,
therefore contributing to the higher susceptibility to vascu-
lar disease of the strain. Interestingly, an epigenetic regula-
tion may be involved in the selective UCP2 gene
downregulation upon HS diet in SHRSP, as suggested by
the evidence obtained in our studies in relation to both
kidney injury [71] and brain damage [74]. Based on the
above-reported evidence, an increase in UCP2 expression
may play a compensatory role to offset, at least in part,
the salt-induced endothelial dysfunction and vascular
damage in hypertension with a consequent net reduction
of adverse outcomes.
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2.4. Stroke. Several findings provide evidence that UCP2 is
directly involved in the development of cerebral ischemic
damage, independent of hypertension. In fact, consistent
with its ability to decrease endogenous mitochondrial
ROS production and to maintain normal mitochondrial
membrane potential and ATP levels, a neuroprotective
effect of UCP2 has been described both in vitro and
in vivo [18, 35, 77–80]. In this regard, both the enhanced
levels of ROS and the apoptosis of neuronal cells are con-
sidered important contributory factors to the cerebral
ischemia/reperfusion injury (I/R), a condition of great
importance among all types of stroke [81]. Of note, it
has been reported that sestrin2 (Sesn2), a powerful free
radical scavenger, exerts a neuroprotective effect during
cerebral I/R injury possibly by increasing mitochondrial
biogenesis. Sesn2 is a member of the sestrin family, which
is a group of highly conserved proteins that are induced
by environmental stresses, including DNA damage, oxida-
tive stress, and hypoxia [82]. Importantly, Sesn2 silencing
suppressed AMPK activation, leading to downregulation
of UCP2, superoxide dismutase 2 (SOD2), peroxisome
proliferator-activated receptor-gamma coactivator (PGC)-
1α, and the downstream signaling factors with resulting
decreased mitochondrial biogenesis and enhanced intrace-
rebral oxidative stress. Thus, Sesn2 provides useful indirect
evidence of the beneficial role of UCP2 in stroke.
2.5. Peripheral Vascular Disease. Evidence obtained by a
microarray approach in human aortic specimens demon-
strated that the UCP2 gene is markedly downregulated in
the aortic occlusive disease [83], a common cause of mor-
bidity and mortality in elderly population. Moreover, a study
performed in a Caucasian general population revealed that
the −866G>A variant of the UCP2 promoter was modestly
associated with asymptomatic carotid atherosclerosis in
middle-aged women [84].
3. UCP2 as a Potential Therapeutic Target for
the Treatment of Vascular Diseases
Several studies suggested that excessive ROS production is
involved in the atherosclerotic plaque formation [85] and
that all plaque cellular components may respond to and
be damaged by ROS. The latter contribute to plaque
progression and finally to plaque rupture [86]. Thus,
several approaches to stop ROS production and to modify
disease progression may be used to treat atherosclerosis
and its dreadful consequences.
Although UCP2 negatively regulates intracellular ROS
production and protects vascular function, its contribu-
tion to the vascular benefits of drugs used to treat cardio-
metabolic diseases is not completely known. Both in vitro
and in vivo studies reviewed herein strongly highlight the
role of UCP2 as a potential therapeutic target for the
treatment of vascular diseases. In particular, UCP2 might
function as an adaptive antioxidant defense to protect
against the development of atherosclerosis in response
to high-fat and cholesterol diets [40, 87] and to improve
hyperglycemia-induced endothelial dysfunction [43]. In
this regard, diabetes might derive a major benefit from
UCP2-targeted therapies. In fact, despite considerable evi-
dence showing beneficial effects of antioxidants, results
from large-scale clinical trials led to the conclusion that
classic antioxidant scavengers may not be appropriate thera-
peutics in diabetes [88]. Therapeutic approaches specifically
designed to counteract glucose-induced mitochondrial ROS
production in the vasculature are expected to show major
efficacy against all diabetic complications, but direct pharma-
cological targeting (scavenging) of mitochondrial oxidants
remains challenging due to the high reactivity of some of
these oxidant species.
The following paragraphs will discuss the available indi-
rect evidence documenting the role of UCP2 as a mediator
of the vascular protective effects exerted by either drugs or
vegetable extracts.
3.1. UCP2 and Its Involvement in the Effects of
Pharmacological Therapy. It has been recently shown that
glucocorticoids induce the expression of the UCP2 protein
[89]. In fact, UCP2 silencing prevented the protective effect
of glucocorticoids on ROS production. UCP2 induction
upon glucocorticoids increased the oxygen consumption
and the proton leak in microvascular hyperglycemic endo-
thelial cells [89]. Thus, UCP2 activation may represent an
attractive experimental therapeutic intervention for the treat-
ment of diabetic vascular complications. While direct use of
glucocorticoids may not be feasible for the treatment of dia-
betic complications, due to the significant side effects that
develop during their chronic administration, the UCP2 path-
way may be therapeutically targetable by other
glucocorticoid-independent pharmacological tools.
A recent study demonstrated that a highly selective
dipeptidyl peptidase-4 inhibitor, sitagliptin, used for the
treatment of diabetes, protected endothelial function in
hypertension through the upregulation of UCP2 expression
and the subsequent scavenging of mitochondrial ROS [90].
The latter phenomenon, in turn, downregulated cyclooxy-
genase- (COX-) 2 expression via the stimulation of the
glucagon-like peptide- (GLP-) 1/GLP-1R/AMPK cascade.
UCP2 inhibited oxidative stress and downregulated COX-2
expression through the GLP-1/GLP-1R/AMPK axis. In
humans, dipeptidyl peptidase-4 inhibitors appear to have
unique and/or additive antiatherosclerotic effects as add-on
therapy to statins and/or angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers [91]. Thus,
UCP2 is revealed as an effective molecular target for drug
intervention to combat both diabetes- and hypertension-
related vascular diseases.
In the context of hypertension, the mitochondrial dys-
function contributes to the promotion of target vascular
damage [92]. Mitochondrial abnormalities were described
in the heart and in the brain of SHR [93, 94], in the kid-
neys of both renovascular and essential hypertensive
animal models [95, 96], and in the brain of SHRSP [97,
98]. Interestingly, a significant protective effect on both
renal and cerebrovascular damage was described with
fenofibrate in salt-loaded SHRSP [97]. This beneficial
effect may be mostly mediated by the peroxisome-
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proliferator activated receptor alpha (PPARα) agonist
action of fibrates with the consequent stimulation, among
other properties, of UCP2 expression [99]. The latter may
exert protective effects on target organ damage through its
action on mitochondrial biogenesis and function. In fact,
we recently obtained evidence that fenofibrate stimulates
brain UCP2 expression, reduces tissue oxidative stress and
inflammation, and exerts full protection from stroke occur-
rence in salt-loaded SHRSP [74]. At the cellular and tissue
levels, PPARα activity mitigates atherosclerosis by blocking
macrophage foam cell formation, vascular inflammation,
vascular smooth muscle cell proliferation and migration,
plaque instability, and thrombogenicity [100]. Interestingly,
clinical use of the synthetic PPARα agonist fibrate has been
reported to reduce cardiovascular risk particularly in high-
risk patients [101].
3.2. The Effects of Vegetables and Plant Extracts on UCP2
Gene and Protein Modulation. We obtained evidence of a
significant stimulation of renal UCP2 expression by the
administration of a vegetable extract obtained from Brassica
oleracea sprouts in the animal model of salt-loaded
SHRSP. In fact, the latter was able to counteract the HS
diet-induced renal damage of SHRSP, independent of BP
levels [102], and to reduce the stroke occurrence of the
strain [74]. The key role of UCP2 stimulation in mediating
the positive effects of Brassica oleracea sprout extract was
reinforced by evidence that parallel blockade with a selective
inhibitor of PPARα did not allow any further protection from
both cerebrovascular and renal damages in HS-fed SHRSP
[74, 102]. Therefore, restoring UCP2 expression levels, as
observed under the Brassica oleracea sprout extract, appears
to be a critical step to prevent target organ damage develop-
ment in hypertension.
Of note, the beneficial cardiovascular effects of vegetable
compounds, including extracts from Brassica oleracea, were
also reported in humans, thus underscoring the potential
useful role of this vegetable as an adjuvant to conventional
cardiovascular therapies [103].
Interestingly, the improvement of mitochondrial func-
tion by the vegetable administration is often mediated
through UCP2 upregulation. Curcumin is an extract from
the Curcuma longa (turmeric) plant rhizome that has been
widely used worldwide as a spice and an herbal medicine.
Curcumin has many biological activities, including the
amelioration of ischemic stroke and antioxidant, anti-inflam-
matory, and antineurodegenerative properties [104, 105].
Chronic dietary curcumin administration significantly
reduced ROS production and improved cerebrovascular
endothelium-dependent relaxation in ageing wild-type mice,
but not in ageing UCP2−/− mice [106]. Dietary curcumin
administration for one month remarkably restored the
impaired cerebrovascular endothelium-dependent vasorelax-
ation in ageing Sprague Dawley rats. In cerebral arteries from
this rat model and in cultured endothelial cells, curcumin
promoted endothelial nitric oxide synthase (eNOS) and
AMPK phosphorylation, upregulated UCP2, and reduced
ROS production. The effects of curcumin were abolished
by either AMPK or UCP2 inhibition [106]. Thus, the
curcumin-mediated UCP2 upregulation involved AMPK
activation in the cerebrovascular endothelium. This activa-
tion antagonized superoxide anion production and prevented
the NO reduction in endothelial cells [106].
Berberine, a botanical alkaloid purified from Rhizoma
coptidis and a constituent of many medicinal plant
extracts, improves metabolic conditions in dyslipidemia,
obesity, and T2DM [107]. Berberine reduces body weight
and improves glucose tolerance and insulin action in obese
and/or diabetic mice by activating the AMPK [108]. Nota-
bly, berberine increases AMPK1α and UCP2 mRNA in
visceral adipose tissues and livers of high-fat diet-fed mice
[109]. In cultured HUVECs, berberine significantly
increased UCP2 mRNA and protein expression in an
AMPK-dependent manner with promotion of mitochon-
drial biogenesis [110]. Transfection of HUVECs with
nuclear respiratory factor 1- (NRF1-) specific siRNA atten-
uated berberine-induced expression of UCP2. Through the
same mechanism, a significant reduction of atherosclerotic
aortic lesions was observed in both ApoE−/− and ApoE−/
−/AMPK alpha 2−/− mice [110].
Capsaicin is a phytochemical responsible for the spic-
iness of peppers [111]. It has the potential to modulate
the metabolism via activation of one of the components
of the transient receptor potential (TRP) channel family,
the TRP vanilloid 1 (TRPV1). The TRP channel family
plays a key role in the regulation of cellular calcium
signaling and of cardiometabolic functions [112]. In
particular, activation of TRPV1, found not only on noci-
ceptive sensory neurons but also in a range of other tis-
sues [112, 113], induces calcium influx, and in certain
tissues, this is associated with increased activation or
expression of key proteins such as eNOS, UCP2,
Krüppel-like factor (KLF2), PPARδ and PPARγ, and liver
X receptor alpha (LXRα) [113]. The increased expression
of UCP2 induced by TRPV1 activation exerts a protective
antioxidant effect in the liver in the nonalcoholic fatty
liver disease and in the vascular endothelium in the
context of hyperglycemia. In rodent studies, capsaicin-
rich diets have shown favorable effects on atherosclerosis,
metabolic syndrome, diabetes, obesity, nonalcoholic fatty
liver disease, cardiac hypertrophy, hypertension, and
stroke [114]. The upregulation of protein kinase A/
UCP2 via TRPV1 activation ameliorated coronary dys-
function and prolonged the lifespan of atherosclerotic
mice by improving endothelial mitochondrial function.
On the other hand, either TRPV1 or UCP2 deficiency
exacerbated high-fat diet-induced coronary dysfunction,
and this result was associated with increased ROS gener-
ation and reduced NO production [114]. Topical applica-
tion of capsaicin via patch was found to increase exercise
time to ischemic threshold in patients with angina [115].
Thus, dietary capsaicin supplementation may represent a
promising intervention for the primary prevention of
coronary heart disease [115]. Further clinical studies with
capsaicin administered in food and capsules, or via patch,
are needed to establish protocols that are tolerable for
most patients and to evaluate the potential of capsaicin
for promoting vascular and metabolic health.
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4. Conclusions
Mitochondrial dysfunction is an emerging contributory
mechanism into the pathogenesis of human vascular dis-
eases. For these reasons, novel targeted approaches, designed
towards mitochondrial-dependent pathogenic mechanisms,
may reveal a useful therapeutic strategy through their ability
to improve mitochondrial function and therefore to protect
patients from cardiovascular disease occurrence [116].
Among the mitochondrial proteins, UCP2 has been revealed
as a significant player in the protection from vascular damage
since lack of UCP2 leads to increased micro- and macrovas-
cular damage in distinct pathological contexts. The fine
molecular mechanisms dependent on the lack of the UCP2
protein, such as ROS accumulation, upregulation of inflam-
matory cytokines, increase in monocyte adhesion and trans-
endothelial migration, and increased cell death, may well
explain the observed increased rate of atherogenesis and
related clinical consequences, as well as the shorter lifespan.
Therefore, UCP2 may represent an attractive and promising
therapeutic tool in cardiovascular therapeutic. Based on the
current knowledge that has been reviewed herein, particu-
larly on the effects of sitagliptin, fibrate, and vegetable
extracts, it is likely that overexpression of UCP2, with a con-
sequent improvement of mitochondrial biogenesis and func-
tion, may represent a mechanism by which a therapeutic
agent can modulate vascular oxidative stress and exert vascu-
lar protection (Figure 2). However, the regulation of UCP2
expression is still a complex and incompletely understood
process, and there is no specific pharmacological tool avail-
able yet to induce UCP2 gene transcription.
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factors known to positively modulate UCP2 gene transcription. As a consequence of the UCP2 protein overexpression, several beneficial
effects are observed in the vascular system with a significant reduction of the vascular disease occurrence.
7Oxidative Medicine and Cellular Longevity
References
[1] S. Diano and T. L. Horvath, “Mitochondrial uncoupling
protein 2 (UCP2) in glucose and lipid metabolism,” Trends
in Molecular Medicine, vol. 18, no. 1, pp. 52–58, 2012.
[2] L. T. Dalgaard and O. Pedersen, “Uncoupling proteins:
functional characteristics and role in the pathogenesis of
obesity and type II diabetes,” Diabetologia, vol. 44, no. 8,
pp. 946–965, 2001.
[3] A. Ledesma, M. G. de Lacoba, and E. Rial, “The mitochon-
drial uncoupling proteins,” Genome Biology, vol. 3, no. 12,
pp. reviews3015.1–reviews3015.9, 2002.
[4] D. Ricquier and F. Bouillaud, “The uncoupling protein
homologues: UCP1, UCP2, UCP3, StUCP and AtUCP,” The
Biochemical Journal, vol. 345, Part 2, pp. 161–179, 2000.
[5] M. Yamada, T. Hashida, N. Shibusawa et al., “Genomic orga-
nization and promoter function of the mouse uncoupling
protein 2 (UCP2) gene,” FEBS Letters, vol. 432, no. 1-2,
pp. 65–69, 1998.
[6] C. Pecqueur, M. C. Alves-Guerra, C. Gelly et al., “Uncou-
pling protein 2, in vivo distribution, induction upon oxida-
tive stress, and evidence for translational regulation,” The
Journal of Biological Chemistry, vol. 276, no. 12,
pp. 8705–8712, 2001.
[7] A. M. Bugge, M. Siersbæk, S. Madsen, A. C. Rougier, and
S. Mandrup, “A novel intronic peroxisome proliferator
activated receptor γ enhancer in the uncoupling protein
(UCP) 3 gene as a regulator of both UCP2 and -3 expres-
sion in adipocytes,” The Journal of Biological Chemistry,
vol. 285, no. 23, pp. 17310–17317, 2010.
[8] K. S. Echtay, M. P. Murphy, R. A. J. Smith, D. A. Talbot, and
M. D. Brand, “Superoxide activates mitochondrial uncou-
pling protein 2 from the matrix side. Studies using targeted
antioxidants,” The Journal of Biological Chemistry, vol. 277,
no. 49, pp. 47129–47135, 2002.
[9] K. S. Echtay, D. Roussel, J. St-Plerre et al., “Superoxide acti-
vates mitochondrial uncoupling proteins,” Nature, vol. 415,
no. 6867, pp. 96–99, 2002.
[10] B. C. Chan and M. E. Harper, “Uncoupling proteins: role in
insulin resistance and insulin insufficiency,” Current Diabetes
Reviews, vol. 2, no. 3, pp. 271–283, 2006.
[11] C. Fleury, M. Neverova, S. Collins et al., “Uncoupling pro-
tein-2: a novel gene linked to obesity and hyperinsulinemia,”
Nature Genetics, vol. 15, no. 3, pp. 269–272, 1997.
[12] B. Miroux, V. Frossard, S. Raimbault, D. Ricquier, and F.
Bouillaud, “The topology of the brown adipose tissue
mitochondrial uncoupling protein determined with anti-
bodies against its antigenic sites revealed by a library of
fusion proteins,” The EMBO Journal, vol. 12, no. 10,
pp. 3739–3745, 1993.
[13] M. J. Berardi, W. M. Shih, S. C. Harrison, and J. J. Chou,
“Mitochondrial uncoupling protein 2 structure determined
by NMR molecular fragment searching,” Nature, vol. 476,
no. 7358, pp. 109–113, 2011.
[14] B. D. Fink, Y. S. Hong, M. M. Mathahs, T. D. Scholz, J. S.
Dillon, and W. I. Sivitz, “UCP2-dependent proton leak in
isolated mammalian mitochondria,” The Journal of Biological
Chemistry, vol. 277, no. 6, pp. 3918–3925, 2002.
[15] Y. Hong, B. D. Fink, J. S. Dillon, and W. I. Sivitz, “Effects of
adenoviral overexpression of uncoupling protein-2 and -3
on mitochondrial respiration in insulinoma cells,” Endocri-
nology, vol. 142, no. 1, pp. 249–256, 2001.
[16] C. Y. Zhang, G. Baffy, P. Perret et al., “Uncoupling protein-2
negatively regulates insulin secretion and is a major link
between obesity, beta cell dysfunction, and type 2 diabetes,”
Cell, vol. 105, no. 6, pp. 745–755, 2001.
[17] G. Mattiasson and P. G. Sullivan, “The emerging functions of
UCP2 in heath, disease, and therapeutics,” Antioxidants &
Redox Signaling, vol. 8, no. 1-2, pp. 1–38, 2006.
[18] G. Mattiasson, M. Shamloo, G. Gido et al., “Uncoupling
protein-2 prevents neuronal death and diminishes brain dys-
function after stroke and brain trauma,” Nature Medicine,
vol. 9, no. 8, pp. 1062–1068, 2003.
[19] M. D. Brand and T. C. Esteves, “Physiological functions of the
mitochondrial uncoupling proteins UCP2 and UCP3,” Cell
Metabolism, vol. 2, no. 2, pp. 85–93, 2005.
[20] F. Bouillaud, “UCP2, not a physiologically relevant uncou-
pler but a glucose sparing switch impacting ROS produc-
tion and glucose sensing,” Biochimica et Biophysica Acta
(BBA) - Bioenergetics, vol. 1787, no. 5, pp. 377–383, 2009.
[21] A. Y. Andreyev, Y. E. Kushnareva, and A. A. Starkov,
“Mitochondrial metabolism of reactive oxygen species,”
Biochemistry, vol. 70, no. 2, pp. 200–214, 2005.
[22] K. Yang, X. Xu, L. Nie et al., “Indoxyl sulfate induces oxida-
tive stress and hypertrophy in cardiomyocytes by inhibiting
the AMPK/UCP2 signaling pathway,” Toxicology Letters,
vol. 234, no. 2, pp. 110–119, 2015.
[23] X. B. Ji, X. R. Li, S. Q. Hao-Ding et al., “Inhibition of uncou-
pling protein 2 attenuates cardiac hypertrophy induced by
transverse aortic constriction in mice,” Cellular Physiology
and Biochemistry, vol. 36, no. 5, pp. 1688–1698, 2015.
[24] M. Y. Lee and K. K. Griendling, “Redox signaling, vascular
function, and hypertension,” Antioxidants & Redox Sig-
naling, vol. 10, no. 6, pp. 1045–1059, 2008.
[25] S. Rubattu, B. Pagliaro, G. Pierelli et al., “Pathogenesis of
target organ damage in hypertension: role of mitochondrial
oxidative stress,” International Journal of Molecular Sciences,
vol. 16, no. 1, pp. 823–839, 2015.
[26] R. R. Nazarewicz, A. E. Dikalova, A. Bikineyeva, and S. I.
Dikalov, “Nox2 as a potential target of mitochondrial super-
oxide and its role in endothelial oxidative stress,” American
Journal of Physiology-Heart and Circulatory Physiology,
vol. 305, no. 8, pp. H1131–H1140, 2013.
[27] E. Yu, J. Mercer, and M. Bennett, “Mitochondria in vascular
disease,” Cardiovascular Research, vol. 95, no. 2, pp. 173–
182, 2012.
[28] M. D. Brand, C. Affourtit, T. C. Esteves et al., “Mitochondrial
superoxide: production, biological effects, and activation of
uncoupling proteins,” Free Radical Biology and Medicine,
vol. 37, no. 6, pp. 755–767, 2004.
[29] L. Liu, J. Liu, Y. Gao, X. Yu, G. Xu, and Y. Huang, “Uncou-
pling protein-2 mediates the protective action of berberine
against oxidative stress in rat insulinoma INS-1E cells and
in diabetic mouse islets,” British Journal of Pharmacology,
vol. 171, no. 13, pp. 3246–3254, 2014.
[30] Z. Xie, J. Zhang, J. Wu, B. Viollet, and M. H. Zou, “Upreg-
ulation of mitochondrial uncoupling protein-2 by the
AMP-activated protein kinase in endothelial cells attenuates
oxidative stress in diabetes,” Diabetes, vol. 57, no. 12,
pp. 3222–3230, 2008.
[31] R. D. Hwang, L. Wiemerslage, C. J. LaBreck et al., “The neu-
roprotective effect of human uncoupling protein 2 (hUCP2)
requires cAMP-dependent protein kinase in a toxin model
8 Oxidative Medicine and Cellular Longevity
of Parkinson’s disease,” Neurobiology of Disease, vol. 69,
pp. 180–191, 2014.
[32] L. Li, G. Yang, S. Shi, M. Yang, H. Liu, and G. Boden, “The
adipose triglyceride lipase, adiponectin and visfatin are
downregulated by tumor necrosis factor-α (TNF-α)
in vivo,” Cytokine, vol. 45, no. 1, pp. 12–19, 2009.
[33] A. Gómez-Hernández, L. Perdomo, N. de las Heras et al.,
“Antagonistic effect of TNF-alpha and insulin on uncoupling
protein 2 (UCP-2) expression and vascular damage,” Cardio-
vascular Diabetology, vol. 13, p. 108, 2014.
[34] C. Merial, A. Bouloumie, V. Trocheris, M. Lafontan, and J.
Galitzky, “Nitric oxide-dependent downregulation of adi-
pocyte UCP-2 expression by tumor necrosis factor-α,”
American Journal of Physiology - Cell Physiology, vol. 279,
no. 4, pp. C1100–C1106, 2000.
[35] B. A. Haines, S. L. Mehta, S. M. Pratt, C. H.Warden, and P. A.
Li, “Deletion of mitochondrial uncoupling protein-2
increases ischemic brain damage after transient focal ische-
mia by altering gene expression patterns and enhancing
inflammatory cytokines,” Journal of Cerebral Blood Flow &
Metabolism, vol. 30, no. s, pp. 1825–1833, 2010.
[36] J. W. Ryu, K. H. Hong, J. H. Maeng et al., “Overexpression of
uncoupling protein 2 in THP1 monocytes inhibits β2
integrin-mediated firm adhesion and transendothelial migra-
tion,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 24, no. 5, pp. 864–870, 2004.
[37] C. Y. Cheung, M. K. Ikram, C. Sabanayagam, and T. Y.
Wong, “Retinal microvasculature as a model to study the
manifestations of hypertension,” Hypertension, vol. 60,
no. 5, pp. 1094–1103, 2012.
[38] J. H. Kim, D. J. Kim, H. C. Jang, and S. H. Choi, “Epidemiol-
ogy of micro- and microvascular complications of type 2 dia-
betes in Korea,” Diabetes & Metabolism Journal, vol. 35,
no. 6, pp. 571–577, 2011.
[39] F. Feihl, L. Liaudet, and B. Waeber, “The macrocirculation
and microcirculation of hypertension,” Current Hypertension
Reports, vol. 11, no. 3, pp. 182–189, 2009.
[40] F. Moukdar, J. Robidoux, O. Lyght, J. Pi, K. W. Daniel,
and S. Collins, “Reduced antioxidant capacity and diet-
induced atherosclerosis in uncoupling protein-2-deficient
mice,” Journal of Lipid Research, vol. 50, no. 1, pp. 59–70,
2009.
[41] Z. B. Andrews and T. L. Horvath, “Uncoupling protein-2
regulates lifespan in mice,” American Journal of Physiology -
Endocrinology and Metabolism, vol. 296, no. 4, pp. E621–
E627, 2009.
[42] J. Blanc, M. C. Alves-Guerra, B. Esposito et al., “Protective
role of uncoupling protein 2 in atherosclerosis,” Circulation,
vol. 107, no. 3, pp. 388–390, 2003.
[43] J. Sun, Y. Pu, P. Wang et al., “TRPV1-mediated UCP2
upregulation ameliorates hyperglycemia-induced endothelial
dysfunction,” Cardiovascular Diabetology, vol. 12, p. 69,
2013.
[44] X. Y. Tian, W. T. Wong, A. Xu et al., “Uncoupling protein-2
protects endothelial function in diet-induced obese mice,”
Circulation Research, vol. 110, no. 9, pp. 1211–1216, 2012.
[45] H. S. Kim, K. G. Park, T. B. Koo, S. Huh, and I. K. Lee, “The
modulating effects of the overexpression of uncoupling
protein 2 on the formation of reactive oxygen species in
vascular cells,” Diabetes Research and Clinical Practice,
vol. 77, Supplement 1, pp. S46–S48, 2007.
[46] L. Nordfors, J. Hoffstedt, B. Nyberg et al., “Reduced gene
expression of UCP2 but not UCP3 in skeletal muscle of
human obese subjects,” Diabetologia, vol. 41, no. 8,
pp. 935–939, 1998.
[47] M. De Souza, M. Michels, D. A. Sortica et al., “Polymor-
phisms of the UCP2 gene are associated with glomerular fil-
tration rate in type 2 diabetic patients and with decreased
UCP2 gene expression in human kidney,” PLoS One,
vol. 10, no. 7, article e0132938, 2015.
[48] S. S. Dhamrait, J. W. Stephens, J. A. Cooper et al., “Cardiovas-
cular risk in healthy men and markers of oxidative stress in
diabetic men are associated with common variation in the
gene for uncoupling protein 2,” European Heart Journal,
vol. 25, no. 6, pp. 468–475, 2004.
[49] H. Esterbauer, C. Schneitler, H. Oberkofler et al., “A common
polymorphism in the promoter of UCP2 is associated with
decreased risk of obesity in middle-aged humans,” Nature
Genetics, vol. 28, no. 2, pp. 178–183, 2001.
[50] N. Srivastava, J. Prakash, R. Lakhan, C. G. Agarwal, D. C.
Pant, and B. Mittal, “A common polymorphism in the
promoter of UCP2 is associated with obesity and hyperin-
sulinemia in northern Indians,” Molecular and Cellular
Biochemistry, vol. 337, no. 1-2, pp. 293–298, 2010.
[51] G. Sesti, M. Cardellini, M. A. Marini et al., “A common poly-
morphism in the promoter of UCP2 contributes to the varia-
tion in insulin secretion in glucose-tolerant subjects,”
Diabetes, vol. 52, no. 5, pp. 1280–1283, 2003.
[52] B. R. Palmer, C. L. Devereaux, S. S. Dhamrait et al., “The
common G-866A polymorphism of the UCP2 gene and sur-
vival in diabetic patients following myocardial infarction,”
Cardiovascular Diabetology, vol. 8, p. 31, 2009.
[53] L. Badimon, R. Hernández Vera, and G. Vilahur, “Athero-
thrombotic risk in obesity,” Hämostaseologie, vol. 33, no. 4,
pp. 259–268, 2013.
[54] M. Barot, M. R. Gokulgandhi, S. Patel, and A. K. Mitra,
“Microvascular complications and diabetic retinopathy:
recent advances and future implications,” Future Medicinal
Chemistry, vol. 5, no. 3, pp. 301–314, 2013.
[55] P. Geraldes, J. Hiraoka-Yamamoto, M. Matsumoto et al.,
“Activation of PKC-dδ and SHP-1 by hyperglycemia causes
vascular cell apoptosis and diabetic retinopathy,” Nature
Medicine, vol. 15, no. 11, pp. 1298–1306, 2009.
[56] J. A. Montero, J. M. Ruiz-Moreno, and M. E. Correa, “Intra-
vitreal anti-VEGF drugs as adjuvant therapy in diabetic reti-
nopathy surgery,” Current Diabetes Reviews, vol. 7, no. 3,
pp. 176–184, 2011.
[57] H. P. Hammes, Y. Feng, F. Pfister, and M. Brownlee, “Dia-
betic retinopathy: targeting vasoregression,” Diabetes,
vol. 60, no. 1, pp. 9–16, 2011.
[58] J. L. Wilkinson-Berka, I. Rana, R. Armani, and A. Agrotis,
“Reactive oxygen species, Nox and angiotensin II in angio-
genesis: implications for retinopathy,” Clinical Science,
vol. 124, no. 10, pp. 597–615, 2013.
[59] Z. Zheng, H. Chen, G. Ke et al., “Protective effect of peri-
ndopril on diabetic retinopathy is associated with
decreased vascular endothelial growth factor-to-pigment
epithelium-derived factor ratio: involvement of a
mitochondria-reactive oxygen species pathway,” Diabetes,
vol. 58, no. 4, pp. 954–964, 2009.
[60] Y. He, N. Wang, Y. Shen, Z. Zheng, and X. Xu, “Inhibition of
high glucose-induced apoptosis by UCP2 in human umbilical
9Oxidative Medicine and Cellular Longevity
vein endothelial cells,” International Journal of Molecular
Medicine, vol. 33, pp. 1275–1281, 2014.
[61] P. P. Singh, F. Mahadi, A. Roy, and P. Sharma, “Reactive oxy-
gen species, reactive nitrogen species and antioxidants in
etiopathogenesis of diabetes mellitus type-2,” Indian Journal
of Clinical Biochemistry, vol. 24, no. 4, pp. 324–342, 2009.
[62] M. G. Huerta and J. L. Nadler, “Oxidative stress, inflam-
mation and diabetic complications,” in Diabetes Mellitus:
A Fundamental and Clinical Text, D. LeRoith, J. M.
Olefsky and S. I. Taylor, Eds., Lippincott Williams &
Wilkins, Cleveland, OH, USA, 2003.
[63] N. Cheurfa, D. Dubois-Laforgue, D. A. F. Ferrarezi et al., “The
common −866>A variant in the promoter of UCP2 is associ-
ated with decreased risk of coronary artery disease in type 2
diabetic men,” Diabetes, vol. 57, no. 4, pp. 1063–1068, 2008.
[64] J. Titze and E. Ritz, “Salt and its effect on blood pressure and
target organ damage: new pieces in an old puzzle,” Journal of
Nephrology, vol. 22, no. 2, pp. 177–189, 2009.
[65] A. Bihorac, H. Tezcan, C. Ozener, A. Oktay, and E. Akoglu,
“Association between salt sensitivity and target organ damage
in essential hypertension,” American Journal of Hypertension,
vol. 13, no. 8, pp. 864–872, 2000.
[66] H. E. de Wardener and G. A. MacGregor, “Harmful effects of
dietary salt in addition to hypertension,” Journal of Human
Hypertension, vol. 16, no. 4, pp. 213–223, 2002.
[67] S. Ma, L. Ma, D. Yang et al., “Uncoupling protein 2 ablation
exacerbates high-salt intake-induced vascular dysfunction,”
American Journal of Hypertension, vol. 23, no. 8, pp. 822–
828, 2010.
[68] S. Ma, Y. Zhang, Q.Wang et al., “Ablation of uncoupling pro-
tein 2 exacerbates salt-induced cardiovascular and renal
remodeling associated with enhanced oxidative stress,” Inter-
national Journal of Cardiology, vol. 175, no. 1, pp. 206–210,
2014.
[69] S. Ma, Q. Wang, Y. Zhang et al., “Transgenic overexpression
of uncoupling protein 2 attenuates salt-induced vascular dys-
function by inhibition of oxidative stress,” American Journal
of Hypertension, vol. 27, no. 3, pp. 345–354, 2014.
[70] S. Rubattu, M. Volpe, U. Ganten, D. Ganten, R. Kreutz, and
K. Lindpaintner, “Chromosomal mapping of a quantitative
trait locus for stroke in an animal model of complex human
disease,” Nature Genetics, vol. 13, pp. 427–432, 1996.
[71] S. Di Castro, S. Scarpino, S. Marchitti et al., “Differential
modulation of uncoupling protein 2 in kidneys of stroke-
prone spontaneously hypertensive rats under high-salt/low
potassium diet,” Hypertension, vol. 61, no. 2, pp. 534–541,
2013.
[72] S. Rubattu, R. Stanzione, and M. Volpe, “Mitochondrial dys-
function contributes to hypertensive target organ damage:
lessons from an animal model of human disease,” Oxidative
Medicine and Cellular Longevity, vol. 2016, Article ID
1067801, 10 pages, 2016.
[73] S. Rubattu, M. Cotugno, F. Bianchi et al., “A differential
expression of uncoupling protein 2 associates with renal
damage in SHRSR/SHRSP-derived stroke congenic lines,”
Journal of Hypertension, vol. 35, no. 9, pp. 1857–1871, 2017.
[74] S. Rubattu, R. Stanzione, F. Bianchi et al., “Reduced brain
UCP2 expression mediated by microRNA-503 contributes
to increased stroke susceptibility in the high-salt fed stroke-
prone spontaneously hypertensive rat,” Cell Death & Disease,
vol. 8, no. 6, article e2891, 2017.
[75] S. Rubattu, F. Bianchi, C. L. Busceti et al., “Differential
modulation of AMPK/PPARα/UCP2 axis in relation to
hypertension and aging in the brain, kidneys and heart
of two closely related spontaneously hypertensive rat strains,”
Oncotarget, vol. 6, no. 22, pp. 18800–18818, 2015.
[76] G. Rose, P. Crocco, F. De Rango, A. Montesanto, and G.
Passarino, “Further support to the uncoupling-to-survive
theory: the genetic variation of human UCP genes is asso-
ciated with longevity,” PLoS One, vol. 6, no. 12, article
e29650, 2011.
[77] D. T. Hass and C. J. Barnstable, “Uncoupling protein 2 in the
glial response to stress: implications for neuroprotection,”
Neural Regeneration Research, vol. 11, no. 8, pp. 1197–1200,
2016.
[78] K. P. Normoyle, M. Kim, A. Farahvar, D. LIano, K. Jacson,
and H. Wang, “The emerging neuroprotective role of
mitochondrial uncoupling protein-2 in traumatic brain
injury,” Translational Neuroscience, vol. 6, no. 1,
pp. 179–186, 2015.
[79] D. W. Lapp, S. S. Zhang, and C. J. Barnstable, “Stat3 mediates
LIF-induced protection of astrocytes against toxic ROS by
upregulating the UCP2 mRNA pool,” Glia, vol. 62, no. 2,
pp. 159–170, 2014.
[80] P. W. Ho, H. F. Liu, J. W. Ho et al., “Mitochondrial uncou-
pling protein-2 (UCP2) mediates leptin protection against
MPP+ toxicity in neuronal cells,” Neurotoxicity Research,
vol. 17, no. 4, pp. 332–343, 2010.
[81] A. Tewari, V. Mahendru, A. Sinha, and F. Bilotta, “Anti-
oxidants: the new frontier for translational research in
cerebroprotection,” Journal of Anaesthesiology Clinical
Pharmacology, vol. 30, no. 2, pp. 160–171, 2014.
[82] L. Li, L. Xiao, Y. Hou et al., “Sestrin2 silencing exacerbates
cerebral ischemia/reperfusion injury by decreasing mito-
chondrial biogenesis through the AMPK/PGC-1α pathway
in rats,” Scientific Reports, vol. 6, article 30272, 2016.
[83] E. Biros, G. Gabel, C. S. Moran et al., “Differential gene
expression in human abdominal aortic aneurysm and aortic
occlusive disease,” Oncotarget, vol. 6, no. 15, pp. 12984–
12996, 2015.
[84] H. Oberkofler, B. Iglseder, K. Klein et al., “Associations of the
UCP2 gene locus with asymptomatic carotid atherosclero-
sis in middle-aged women,” Arteriosclerosis Thombosis
and Vascular Biology, vol. 25, no. 3, pp. 604–610, 2005.
[85] G. M. Chisolm and D. Steinberg, “The oxidative modification
hypothesis of atherogenesis: an overview,” Free Radical
Biology and Medicine, vol. 28, no. 12, pp. 1815–1826, 2000.
[86] Z. Mallat, T. Nakamura, J. Ohan et al., “The relationship of
hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque
instability in human carotid atherosclerosis,” The Journal of
Clinical Investigation, vol. 103, no. 3, pp. 421–427, 1999.
[87] T. Kizaki, K. Suzuki, Y. Hitomi et al., “Uncoupling protein 2
plays an important role in nitric oxide production of
lipopolysaccharide-stimulated macrophages,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 99, no. 14, pp. 9392–9397, 2002.
[88] J. S. Johansen, A. K. Harris, D. J. Rychly, and A. Ergul,
“Oxidative stress and the use of antioxidants in diabetes:
linking basic science to clinical practice,” Cardiovascular
Diabetology, vol. 4, p. 5, 2005.
[89] D. Gerö and C. Szabo, “Glucocorticoids suppress mitochon-
drial oxidant production via upregulation of uncoupling
10 Oxidative Medicine and Cellular Longevity
protein 2 in hyperglycemic endothelial cells,” PLoS One,
vol. 11, no. 4, article e0154813, 2016.
[90] L. Liu, J. Liu, X. T. Yu et al., “Uncoupling protein-2 mediates
DPP-4 inhibitor-induced restoration of endothelial function
in hypertension through reducing oxidative stress,” Antioxi-
dants & Redox Signaling, vol. 21, no. 11, pp. 1571–1581, 2014.
[91] T. Mita, N. Katakami, T. Shiraiwa et al., “Changes in carotid
intima-media thickening in patients with type 2 diabetes mel-
litus: Subanalysis of the Sitagliptin Preventive Study of
Intima-Media Thickness Evaluation,” Journal of Diabetes
Investigation, vol. 8, no. 2, pp. 254-255, 2017.
[92] S. Rubattu, B. Pagliaro, G. Pierelli et al., “Pathogenesis of
target organ damage in hypertension: role of mitochondrial
oxidative stress,” International Journal Molecular Sciences,
vol. 16, no. 1, pp. 823–839, 2014.
[93] J. Q. D. Rodrigues, E. D. Da Silva Jr, K. De Magalh et al., “Dif-
ferential regulation of atrial contraction by P1 and P2 purino-
ceptors in normotensive and spontaneously hypertensive
rats,” Hypertension Research, vol. 37, pp. 210–219, 2014.
[94] S. Onoue, Y. Kumon, K. Igase, T. Ohnishi, and M. Sakanaka,
“Growth arrest and DNA damage-inducible gene 153
increases transiently in the thalamus following focal cerebral
infarction,” Molecular Brain Research, vol. 134, no. 2,
pp. 189–197, 2005.
[95] E. M. V. De Cavanagh, J. E. Toblli, L. Ferder, B. Piotrkowski,
I. Stella, and F. Inserra, “Renal mitochondrial dysfunction
in spontaneously hypertensive rats is attenuated by losartan
but not by amlodipine,” American Journal Physiology-
Regulatory Integrative Comparative Physiology, vol. 290,
no. 6, pp. R1616–R1625, 2006.
[96] A. Eirin, Z. Li, X. Zhang et al., “Amitochondrial permeability
transition pore inhibitor improves renal outcomes after
revascularization in experimental atherosclerotic renal artery
stenosis,” Hypertension, vol. 60, no. 5, pp. 1242–1249, 2012.
[97] P. Gelosa, C. Banfi, A. Gianella et al., “Peroxisome
proliferator-activated receptor alpha agonism prevents renal
damage and the oxidative stress and inflammatory processes
affecting the brains of stroke-prone rats,” Journal of Pharma-
cology and Experimental Therapeutics, vol. 335, no. 2,
pp. 324–331, 2010.
[98] S. Rubattu, S. Di Castro, H. Schulz et al., “Ndufc2 gene inhi-
bition is associated with mitochondrial dysfunction and
increased stroke susceptibility in an animal model of complex
human disease,” Journal of American Heart Association,
vol. 5, no. 2, 2016.
[99] A. Tomizawa, Y. Hattori, T. Inoue, S. Hattori, and K. Kasai,
“Fenofibrate suppresses microvascular inflammation and
apoptosis through adenosine monophosphate-activated pro-
tein kinase activation,” Metabolism: Clinical and Experimen-
tal, vol. 60, no. 4, pp. 513–522, 2011.
[100] X. H. Yu, X. L. Zheng, and C. K. Tang, “Chapter Seven - per-
oxisome proliferator-activated receptor α in lipid metabolism
and atherosclerosis,” Advances in Clinical Chemistry, vol. 71,
pp. 171–203, 2015.
[101] M. Jun, C. Foote, J. Lv et al., “Effects of fibrates on cardio-
vascular outcomes: a systematic review and meta-analysis,”
Lancet, vol. 375, no. 9729, pp. 1875–1884, 2010.
[102] S. Rubattu, S. Di Castro, M. Cotugno et al., “Protective effects
of Brassica oleracea sprouts extract toward renal damage in
high-salt-fed SHRSP: role of AMPK/PPARα/UCP2 axis,”
Journal of Hypertension, vol. 33, no. 7, pp. 1465–1479, 2015.
[103] B. Pagliaro, C. Santolamazza, F. Simonelli, and S. Rubattu,
“Phytochemical compounds and protection from cardiovas-
cular diseases: a state of the art,” BioMed Research Interna-
tional, vol. 2015, Article ID 918069, 17 pages, 2015.
[104] S. C. Gupta, S. Patchva, W. Koh, and B. B. Aggarwal, “Dis-
covery of curcumin, a component of golden spice, and its
miraculous biological activities,” Clinical and Experimental
Pharmacology & Physiology, vol. 39, no. 3, pp. 283–299,
2012.
[105] M. Thiyagarajan and S. S. Sharma, “Neuroprotective effect of
curcumin in middle cerebral artery occlusion induced focal
cerebral ischemia in rats,” Life Sciences, vol. 74, no. 8,
pp. 969–985, 2004.
[106] Y. Pua, H. Zhanga, P. Wanga et al., “Dietary curcumin
ameliorates aging-related cerebrovascular dysfunction
through the AMPK/uncoupling protein 2 pathway,” Cellular
Physiology and Biochemistry, vol. 32, no. 5, pp. 1167–1177,
2013.
[107] H. W. Jeong, K. C. Hsu, J. W. Lee et al., “Berberine suppresses
proinflammatory responses through AMPK activation in
macrophages,” American Journal of Physiology - Endocrinol-
ogy and Metabolism, vol. 296, no. 4, pp. E955–E964, 2009.
[108] W. S. Kim, Y. S. Lee, S. H. Cha et al., “Berberine improves
lipid dysregulation in obesity by controlling central and
peripheral AMPK activity,” American Journal of Physiology
- Endocrinology and Metabolism, vol. 296, no. 4, pp. E812–
E819, 2009.
[109] W. Xie, D. Gu, J. Li, K. Cui, and Y. Zhang, “Effects and action
mechanisms of berberine and Rhizoma coptidis on gut
microbes and obesity in high-fat diet-fed C57BL/6J mice,”
PLoS One, vol. 6, no. 9, article e24520, 2011.
[110] Q. Wang, M. Zhang, B. Liang, N. Shirwany, Y. Zhu, and M.
H. Zou, “Activation of AMP-activated protein kinase is
required for berberine-induced reduction of atherosclerosis
in mice: the role of uncoupling protein 2,” PLoS One, vol. 6,
no. 9, article e25436, 2011.
[111] M. F. McCarty, J. J. Di Nicolantonio, and J. H. O’Keefe, “Cap-
saicin may have important potential for promoting vascular
and metabolic health,” Open Heart, vol. 2, no. 1, article
e000262, 2015.
[112] Z. Zhu, S. Xiong, and Q. Li, “The role of transient receptor
potential channels in hypertension and metabolic vascular
damage,” Experimental Physiology, vol. 101, no. 11,
pp. 1338–1344, 2016.
[113] B. Nilius and A. Szallasi, “Transient receptor potential chan-
nels as drug targets: from the science of basic research to the
art of medicine,” Pharmacological Reviews, vol. 66, no. 3,
pp. 676–814, 2014.
[114] Z. Zhu, Z. Luo, S. Ma, and D. Liu, “TRP channels and their
implications in metabolic diseases,” Pflügers Archiv,
vol. 461, no. 2, pp. 211–223, 2011.
[115] S. Xiong, P. Wang, L. Ma et al., “Ameliorating endothelial
mitochondrial dysfunction restores coronary function via
transient receptor potential vanilloid 1–mediated protein
kinase A/uncoupling protein 2 pathway,” Hypertension,
vol. 67, no. 2, pp. 451–460, 2016.
[116] O. S. Kornfeld, S. Hwang, M. H. Disatnik, C. H. Chen, N.
Qvit, and D. Mochly-Rosen, “Mitochondrial reactive oxygen
species at the heart of the matter: new therapeutic approaches
for cardiovascular diseases,” Circulation Research, vol. 116,
no. 11, pp. 1783–1799, 2015.
11Oxidative Medicine and Cellular Longevity
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
